These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8862722)

  • 1. Daily oral etoposide in metastatic breast cancer.
    Nesković-Konstantinović ZB; Bosnjak SM; Radulović SS; Mitrović LB
    Anticancer Drugs; 1996 Jul; 7(5):543-7. PubMed ID: 8862722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of oral etoposide for patients with advanced breast cancer.
    Atienza DM; Vogel CL; Trock B; Swain SM
    Cancer; 1995 Dec; 76(12):2485-90. PubMed ID: 8625074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.
    Pusztai L; Walters RS; Valero V; Theriault RL; Hortobagyi GN
    Am J Clin Oncol; 1998 Oct; 21(5):442-6. PubMed ID: 9781596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic oral etoposide in advanced breast cancer.
    Palombo H; Estapé J; Viñolas N; Grau JJ; Mañé JM; Daniels M; Mellado B
    Cancer Chemother Pharmacol; 1994; 33(6):527-9. PubMed ID: 8137464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
    Weiss GR; Shaffer DW; DeMoor C; Rinaldi DA; Rodriguez GI; Eckardt JR; Stephens C; Von Hoff DD
    Anticancer Drugs; 1996 Jun; 7(4):402-9. PubMed ID: 8826608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.
    Saphner T; Weller EA; Tormey DC; Pandya KJ; Falkson CI; Stewart J; Robert NJ
    Am J Clin Oncol; 2000 Jun; 23(3):258-62. PubMed ID: 10857889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.
    Bontenbal M; Planting AS; Verweij J; de Wit R; Kruit WH; Stoter G; Klijn JG
    Breast Cancer Res Treat; 1995 May; 34(2):185-9. PubMed ID: 7647335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral etoposide for patients with advanced adenocarcinoma of the pancreas.
    Thomas E; Dumas P; Ajani JA
    Invest New Drugs; 1998-1999; 16(4):333-5. PubMed ID: 10426667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy.
    Schwartsmann G; Sprinz E; Kromfield M; Kalakun L; Sander E; Prolla G; Di Leone L; Gerhardt L; Mans DR
    J Clin Oncol; 1997 May; 15(5):2118-24. PubMed ID: 9164226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of a phase II trial of chronic oral etoposide in breast cancer.
    Martín M; Casado A; Lluch A; Adrover E; Diaz-Rubio E; García-Conde J
    Cancer Treat Rev; 1993; 19 Suppl C():47-52. PubMed ID: 8221716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
    Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
    J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients.
    Jagodic M; Cufer T; Zakotnik B; Cervek J
    Anticancer Drugs; 2001 Mar; 12(3):199-204. PubMed ID: 11290866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
    Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients.
    Valabrega G; Berrino G; Milani A; Aglietta M; Montemurro F
    Breast J; 2015; 21(3):241-5. PubMed ID: 25772707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study with etoposide in previously untreated advanced breast cancer.
    Wander HE; Rauschning W; Meyer D; Achterrath W; Nagel GA
    Cancer Chemother Pharmacol; 1989; 24(4):261-3. PubMed ID: 2752508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.
    Martín M; Lluch A; Casado A; Santabárbara P; Adrover E; Valverde JJ; López-Martín JA; Rodriguez-Lescure A; Azagra P; García-Conde J
    J Clin Oncol; 1994 May; 12(5):986-91. PubMed ID: 8164052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.
    Thomas GW; Muss HB; Jackson DV; McCulloch J; Ramseur W; McFarland J; Hoen H; Pavy M; Heath R
    Cancer Chemother Pharmacol; 1994; 35(2):165-8. PubMed ID: 7987995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.
    Osby E; Liliemark E; Björkholm M; Liliemark J
    Med Oncol; 2001; 18(4):269-75. PubMed ID: 11918453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.